Apolipoprotein (apo) E and the two B apolipoproteins, apoB48 and apoB100, are important proteins in human lipoprotein metabolism. Commonly occurring polymorphisms in the genes for apoE and apoB result in amino acid substitutions that produce readily detectable phenotypic differences in these proteins. We studied changes in apoE and apoB phenotypes before and after liver transplantation to gain new insights into apolipoprotein physiology. In all 29 patients that we studied, the postoperative serum apoE phenotype of the recipient, as assessed by isoelectric focusing, converted virtually completely to that of the donor, providing evidence that greater than 90% of the apoE in the plasma is synthesized by the liver. In contrast, the cerebrospinal fluid apoE phenotype did not change to the donor's phenotype after liver transplantation, indicating that most of the apoE in CSF cannot be derived from the plasma pool and therefore must be synthesized locally. The apoB100 phenotype (assessed with immunoassays using monoclonal antibody MB19, an antibody that detects a two-allele polymorphism in apoB) invariably converted to the phenotype of the donor. In four normolipidemic patients, we determined the MB19 phenotype of both the apoB100 and apoB48 in the "chylomicron fraction" isolated from plasma 3 h after a fat-rich meal. Interestingly, the apoB100 in the chylomicron fraction invariably had the phenotype of the donor, indicating that the vast majority of […] 
Introduction
Apolipoprotein (apo) E and the two B apolipoproteins, apoB48 and apoB100, are important proteins in human lipoprotein metabolism. Commonly occurring polymorphisms in the genes for apoE and apoB result in amino acid substitutions that produce readily detectable phenotypic differences in these proteins. We studied changes in apoE and apoB phenotypes before and after liver transplantation to gain new insights into apolipoprotein physiology. In all 29 patients that we studied, the postoperative serum apoE phenotype of the recipient, as assessed by isoelectric focusing, converted virtually completely to that of the donor, providing evidence that > 90% of the apoE in the plasma is synthesized by the liver. In contrast, the cerebrospinal fluid apoE phenotype did not change to the donor's phenotype after liver transplantation, indicating that most of the apoE in CSF cannot be derived from the plasma pool and therefore must be synthesized locally. The apoB100 phenotype (assessed with immunoassays using monoclonal antibody MB19, an antibody that detects a two-allele polymorphism in apoB) invariably converted to the phenotype of the donor. In four normolipidemic patients, we determined the MB19 phenotype of both the apoB100 and apoB48 in the "chylomicron fraction" isolated from plasma 3 h after a fat-rich meal. Interestingly, the apoB100 in the chylomicron fraction invariably had the phenotype of the donor, indicating that the vast majority of the large, triglyceride-rich apoB100-containing lipoproteins that appear in the plasma after a fat-rich meal are actually VLDL of hepatic origin. The MB19 phenotype of the apoB48 in the plasma chylomicron fraction did not change after liver transplantation, indicating that almost all of the apoB48 in plasma chylomicrons is derived from the intestine. These results were consistent with our immunocytochemical studies on intestinal biopsy specimens of organ donors; using apoB-specific monoclonal antibodies, we found evidence for apoB48, but not apoB100, in donor intestinal biopsy specimens. (J. Clin. Invest. 1991. 88:270-281.) Key words: lipoproteins * cholesterol -genetic polymorphism -monoclonal antibody Orthotopic liver transplantation-the complete removal of a diseased liver and the implantation of a normal liver from a donor-has become a common treatment for end-stage parenchymal liver disease and biliary tract disease (1) . Implantation of the donor liver requires creating the appropriate surgical anastomoses for the biliary duct, the portal vein, the inferior vena cava, and the hepatic artery (1) . Liver transplantation has also been used to treat a large variety ofinborn errors ofmetabolism (1) , including deficiencies of a hepatic membrane receptor, an intracellular enzyme, or a secreted protein. Recently, a familial hypercholesterolemia homozygote with severe atherosclerotic heart disease underwent a combined liver/heart transplantation procedure (2) . Familial hypercholesterolemia is caused by a deficiency of normal LDL receptors, which retards the hepatic clearance of LDL. Postoperatively, the patient had increased hepatic clearance of LDL and only moderate hypercholesterolemia, indicating that the metabolic defect had been partially corrected by the liver transplantation (2) . A patient with tyrosinemia had nearly complete correction ofthat defect with liver transplantation (1, 3) , and both hemophilia A and hemophilia B are correctable by liver transplantation (1, 4, 5) . The extent to which inborn errors of metabolism are corrected after this procedure has frequently yielded fresh insights into the extent of the liver's role in the development of disease (1) .
Our laboratory has focused on the metabolism of apolipoprotein E and the two B apolipoproteins, apoB48 and apoB100. Apolipoprotein E is a major protein component of VLDL (6) , is a ligand for the LDL receptor, and is important for the receptor-mediated uptake of chylomicron and VLDL remnants by the liver. Apolipoprotein E is also found in relatively high levels in the cerebrospinal fluid (CSF),1 and investigators have speculated that it may play an important role in the redistribution of lipids within the brain (7) (8) (9) . Apolipoprotein B48, which contains the amino-terminal 2,152 amino acids of apoB100, is a crucial structural protein in chylomicrons and is generally thought to be synthesized exclusively by the human intestine (10) , although a recent report has suggested that small amounts ofthe protein might be made by the human liver (11) .
Apolipoprotein B100 is a crucial structural protein in the formation of the triglyceride-rich VLDL in the liver (12) , but recent studies have suggested that the human intestine may also synthesize apoB100 (11, (13) (14) (15) (16) (17) .
Studies performed over the past decade have demonstrated that there are commonly occurring polymorphisms in both the apoB and apoE genes (6, 18) . These polymorphisms result in amino acid substitutions and phenotypic changes in the proteins that can be assessed by simple laboratory tests. Isoelectric focusing can be used to characterize commonly occurring phenotypes ofapoE that are due to substitutions involving charged amino acids at residues 112 and 158 (6) . Radioimmunoassays using the apoB-specific monoclonal antibody MBl9 can be used to detect the genetically determined "MB 19 phenotype" in apoB48 and apoB 100 (19) ; the MBl9 polymorphism is perfectly associated with and probably caused by an amino acid substitution at apoB residue 71 (20) .
We initiated a study ofthe changes in apoE and apoB phenotypes after liver transplantation with the expectation that a study in those patients could provide important insights into apolipoprotein physiology. This expectation was fulfilled; the study of liver transplant patients was uniquely informative about several topics in human apolipoprotein physiology. Among the issues addressed in this study were the origin of apoE in serum and CSF, the glycosylation pattern ofthe serum apoE that is derived from extrahepatic sources, the origin ofthe apoE-A-II heterodimers, the origin of apoB48 in fasting plasma, and the origin of the apoB100 that appears in the plasma "chylomicron fraction" after a fat-rich meal.
Methods
Studypopulation. We obtained blood samples from 29 liver transplant recipients in the operating room on the day of their operation. Blood samples from respective organ donor patients were obtained premortem in the operating room before the organs were harvested (i.e., before life support was discontinued). We also obtained blood samples from all the postoperative recipients; these samples were obtained at least 1 mo and usually 2-6 mo after the operation. Serum and plasma (containing 1 mg EDTA/ml) were separated from the blood cells by centrifugation at 4°C, and the samples were frozen at -70°C. Genomic DNA was prepared from the white blood cells (21) . I ml of CSF, which was collected by lumbar puncture for diagnostic purposes, was obtained from six patients. The studies described here were approved by the Human Experimentation Committee of the Pacific Presbyterian Medical Center.
Apolipoprotein E phenotyping. Apolipoprotein E phenotyping was performed by isoelectric focusing (IEF) (22) . The most common apoE isoform is apoE3. Apolipoprotein E4, a more basic isoform, differs from apoE3 in having an arginine-for-cysteine substitution at residue 112. Apolipoprotein E2 is a more acidic isoform and is most commonly the result of a cysteine-for-arginine substitution at residue 158 (6) . In the general population, there are three homozygous apoE phenotypes (E3/3, E4/4, and E2/2) and three heterozygous apoE phenotypes (E4/2, E4/3, and E3/2). Because different apoE isoforms distribute differently within the plasma lipoprotein fractions (23) (24) (25) , we performed apoE phenotyping on whole serum samples using the Western blot IEF system reported by Menzel and Utermann (22) . Only I ul of plasma was loaded onto each lane of the IEF gel. After electrophoresis, the proteins in the gel were electrophoretically transferred to a sheet of nitrocellulose membrane for immunoblotting. Apolipoprotein E-specific antibodies for these studies were kindly provided by Drs. L. Curtiss, K. Weisgraber, and S. Kunitake. Serum from subjects previously characterized as having the apoE3/3, apoE4/4, apoE3/2, and apoE4/3 phenotypes were included as controls on each gel. Phenotyping studies ofCSF apoE were performed by using identical Western blotting techniques. However, the CSF was first concentrated by a SpeedVac Concentrator (Savant Instruments, Farmingdale, NY); the concentrated proteins from 50 ul of CSF were loaded onto each lane of the gel.
Detection ofdisulfide-linked apolipoprotein E complexes. To detect the presence ofapoE-A-II heterodimers (26) and disulfide-linked apoE homodimers (27) To assess the MB19 phenotype of the apoBlOO and apoB48 in VLDL and "chylomicron fractions," we simultaneously determined the MBl9 phenotypes of the electrophoretically separated apoB100 and apoB48 proteins by a double-label Western blot assay (28) . We studied four subjects who had undergone transplantation over 6 mo before the study and had remained clinically well and normolipidemic. 60 ml of blood was obtained from each subject after a 14-h fast and again 2 h after a meal containing 80 g of fat. The blood was collected into tubes containing EDTA (1 mg/ml). The plasma was immediately separated from the blood cells by centrifugation, and protease inhibitors were added to the plasma (34) . The fasting plasma samples were clear, whereas the postprandial plasma samples were turbid in all patients. The VLDL samples were prepared from the plasma samples of fasted subjects by standard ultracentrifugation techniques (31) . The plasma chylomicron fraction was isolated from the postprandial plasma as previously described (28) . Briefly, 15 (35) . Agphenotyping ofserum. Ag phenotyping ofserum was performed by the passive hemagglutination inhibition assay, using human red cells (type 0, Rh-) coated with purified human LDL ofan appropriate phenotype and human Ag antisera with corresponding specificities, as described in detail elsewhere (36) .
To test for the presence ofanti-apoB antibodies with Ag specificity in the postoperative serum ofliver transplant patients, a direct hemagglutination assay was used. Each patient's serum was diluted 1:4 with PBS, and aliquots were incubated separately with a battery ofseven red cell suspensions coated with LDL of different Ag types, covering the full spectrum of the 10 known Ag specificities (36) . The preparation of the LDL-coated red cells and the reaction conditions were exactly the same for the Ag phenotyping discussed above, except that the human anti-Ag serum (used as reagent in the antigen test) was replaced by an equal volume of PBS (36) .
Immunocytochemistry of liver and intestinal biopsy specimens. Liver biopsy specimens as well as duodenal, jejunal, and ileal biopsy specimens were obtained from eight organ donor subjects. Most ofthe organ donors had received only intravenous feedings forthe 24 h before the biopsy procedure. The specimens were immediately fixed in formafin. After 4-12 h of fixation, the samples were washed in PBS and incubated overnight at 4VC in PBS containing 18% sucrose. The tissue was frozen in liquid nitrogen, and cryostat sections were cut, mounted on slides, and incubated in a blocking buffer before being used for immunocytochemistry. The sections were incubated with a wide range of dilutions of mouse ascites fluid containing various apoB-specific monoclonal antibodies for 24 h, washed, and subsequently incubated with biotinylated anti-mouse IgG and then a biotinylated horseradish peroxidase complexed to avidin (Vector Laboratories, San Francisco, CA) as described (37) . For these studies, we used several different apoBspecific monoclonal antibodies (29, 32 ) that bind both apoB48 and apoBl00 (MB24, MBl 1, MB3) and two antibodies specific for the carboxyterminal portion of apoB100 (MB44 and MB43) that bind apoB100 but not apoB48. Peroxidase activity was detected with diaminobenzidine and nickel, and the sections were lightly counterstained with methyl green and then photographed.
Results
We obtained preoperative and postoperative plasma and serum specimens from 29 consecutive liver transplant recipients, and preoperative plasma and serum specimens from their respective organ donors. In three other cases, preoperative and postoperative recipient specimens were available, but no donor specimens were available. -30% of the recipients underwent liver transplantation for biliary tract disease, and 70% for parenchymal liver disease. A single recipient with Wilson's disease represented the only case of an inborn error of metabolism. The mean age of the recipients was 46 yr; only three were younger than 20 yr of age. The mean age for the organ donor patients was 24 , with a range of 4 to 58. 68% of the organ donors had sustained major trauma. Of the deaths from trauma, 65% were due to vehicular accidents. Most ofthe other donors died as a result ofsubarachnoid or intracerebral hemorrhages.
The results ofthe serum apoE phenotyping studies are summarized in Table I . In 11 of 26 cases, the apoE phenotype of donor serum and preoperative recipient serum was identical, so these cases were not informative. However, in 15 cases, the donor and preoperative recipient serum apoE phenotypes were different. In each of these cases, the postoperative recipient serum apoE phenotype converted to that of the donor. In two Fig. 1 . The conversion of the recipient serum apoE phenotype to that of the donor was complete insofar as we could measure. In most cases, the apoE phenotyping system that we used was not sufficiently sensitive to detect in the postoperative recipient serum the presence of an apoE isoform made by the recipient's extrahepatic tissues but not made by the donor liver. Occasionally, however, when examining postoperative recipient serum, prolonged exposure of the autoradiogram of the isoelectric focusing gel did reveal a small amount of an apoE isoform that was present in the preoperative recipient plasma, but not made by the donor liver. For example, the preoperative apoE phenotype ofone ofthe liver transplant recipients was 4/4. 3 mo postoperatively, the phenotype was clearly 3/2, but a very faint apoE4 band was detectable (Fig. 2, lane 5) . Because the half-life of apoE in plasma is only a few hours (23), and because the postoperative recipient blood samples were always taken more than 1 mo after the operation, the apoE4 band must have been due to the synthesis of apoE4 by extrahepatic tissues. In several other cases, we were able to detect a small amount of extrahepatic apoE synthesis (i.e., an apoE isoform made by extrahepatic tissues, but not the donor liver) by loading several micrograms ofdelipidated VLDL proteins, rather than serum, onto the IEF gel (data not shown). We estimate that the extrahepatic contribution to the serum apoE pool invariably represented significantly < 10% of the total serum apoE. Apolipoprotein E is an easily detectable protein component of human and canine CSF (8, 38) . The fact that astrocytes synthesize apoE (7) strongly suggests that a portion ofthe apoE in CSF is produced locally in the brain. However, many serum proteins, particularly those with low molecular weight, are present in the CSF. For example, apoA-I, which has a molecular weight only slightly lower than that of apoE (28 vs (Table II) . The six CSF samples that we obtained from liver transplant patients were sterile and had normal protein and glucose concentrations. Studies in two subjects (subjects 1 and 2 in Table II) were not informative because the apoE phenotype of the preoperative recipient serum and that of the donor serum were identical. However, studies in four other patients (subjects 3-6 in Similarly, in subject 4, the serum apoE phenotype converted from 4/3 to 4/2 postoperatively (Fig. 4, lanes 4 and 5) , but the CSF phenotype remained 4/3 (Fig. 4 , lane 6). Two ofthe liver transplant recipients were particularly interesting because they involved subjects with the 4/4 phenotype. Apolipoprotein E4 contains no cysteine residues and therefore cannot participate in either the formation ofapoE-A-II heterodimers (25) or apoE homodimers (27) . One liver transplant recipient, who had serum apoE phenotype 4/4 preoperatively, converted to phenotype 3/2 postoperatively. No apoE-A-II or apoE dimers were present in'the serum preoperatively ( Fig. 6 ). This was also the case for the apoE homodimer. The minor bands above the apoE homodimer band in lanes 1 and 3 represent various oligomers that are possible because apoE2 contains two cysteine residues (compare with Fig. 6 , lanes I and 3, where no apoE2 exists). The identity of the apoE-A-II complex was confirmed with immunoblots using an apoA-II specific antibody (data not shown).
serum (Fig. 5, lane 3 Fig. 3 illustrates that pate in disulfide-linked dimer formation. Interestingly, in the more heavily sialylated and contains more minor latter recipient, both the apoE-A-II heterodimers and the apoE plasma apoE. Fortunately, with this IEF system, homodimers in the postoperative serum had a slightly higher ,es at a distinctively more basic position than apparent molecular weight compared with those in the preoperipare lanes 3 and 5). The monosialo E3 band in uses more acidically than asialo apoE2. Thus, if ative sample (Fig. 6, lane 2 vs. lane 3) . The higher molecular Lt of asialo apoE2 were present in the CSF of reweight of these disulfide-linked apoE complexes, compared have been detectable above the monosialo E3 band with those found in the preoperative sample and other control samples, was also observed in two subsequent experiments. The slower migration of these disulfide-linked complexes in the postoperative serum was eliminated by neuraminidase treatment of the serum (data not shown). This finding suggests that the serum apoE that is produced in extrahepatic tissues is more heavily glycosylated than the serum apoE that is derived from the liver. The MB 19 phenotype of the apoB100 in plasma was assessed by RIA using the apoB-specific antibody MB 19. Because apoB48 is present in only trace amounts in the plasma, relative to apoB100, RIAs of plasma samples assess only the apoB100 phenotype. The MB 19 phenotype ofthe apoB 100 in postoperative recipient plasma converted to the phenotype of the donor in all four subjects studied (Table III) . Competitive RIAs that demonstrate changes in the MB 19 phenotype of LDL samples are shown in Fig. 7 .
Prior studies have proven that allotypes MB 1 91 and MB 1 92 can be detected by human antisera specific for the Ag(c) and Ag(g) epitopes, respectively (39). The latter two epitopes represent two of 10 different Ag epitopes that can be detected using antisera from multiply transfused thalassemic patients (36) . All 10 antisera were used to analyze the changes in apoB 100 phenotype in 15 liver transplant patients. We found that the postoperative recipient apoB phenotype, as judged by all 10 markers, was invariably identical to that of the donor (Table IV) . Because many liver transplant recipients were exposed to new Ag antigens produced by the donor liver, we tested whether any of the 15 liver transplant recipients had developed antibodies specific for the foreign Ag allotypes produced by the donor liver. However, we did not detect any Ag-specific antibodies in any of the postoperative recipient serum samples, each of which was taken more than 3 mo postoperatively.
To determine whether the MB19 phenotypes of apoB48 changed after liver transplantation, we used a double-label Western blot immunoassay (28, 32) . We obtained plasma from four liver transplant recipients after they had fasted for 14 h, then prepared the VLDL by ultracentrifugation. The apoB100 and apoB48 were separated from the other VLDL apolipoproteins by SDS-PAGE. Examination ofthe postoperative VLDL samples from four normolipidemic liver transplant patients confirmed that the phenotype ofthe apoB 100 converted to that of the donor liver (Table V) . In contrast, the postoperative MBl9 phenotype of the apoB48 was invariably the same as that of the preoperative plasma of the recipient and did not change to the phenotype of the donor (Table V) . We then evaluated the "chylomicrons" that were isolated from plasma obtained from the same four subjects 2 h after a fat-rich meal. (None of the subjects had detectable chylomicrons under fasting conditions.) Examination of the postprandial chylomicrons by Coomassie blue-stained SDS-polyacrylamide slab gels revealed that the apoB 100 band stained slightly more intensely than the apoB48 band (data not shown). This finding was in keeping with the results that we previously observed in normolipidemic control subjects (28) . To exclude the possibility that the apoB100 in this fraction was an artifact resulting from contamination by particles of the LDL size range, we examined each of the chylomicron preparations by negative-stain electron microscopy. The lipoproteins were heterogeneous in size, with most particles having a diameter of 350-1,500 nm. Particles in the LDL size range (< 250 nm) were infrequent (5-10%). The MBl9 phenotypes of the apoB100 and the apoB48 in the chylomicron fractions were examined by the double-label Western blot assay. In each of the four recipients, the MB 19 phenotype of the apoB100 was identical to the MBl9 phenotype of the donor liver, whereas the MB 19 phenotype of the apoB48 was identical to that present in the preoperative plasma of the recipient (Table VI) . These data indicate that the vast majority of the apoB100 that appears in the plasma chylomicron fraction after a fat-rich meal is of hepatic, not intestinal, origin.
Our results with the 1251/131I Western blot assay indicate that the large majority of apoB48 is made in the intestine and that the large majority of apoB100 (even the apoB100 in the somewhat to the left, compared with the curves usually observed with LDL samples having the MB 19JMB 192. This observation is most likely explained by the fact that the donor in C had received 10 U of plasma or whole blood within 12 h of the liver-harvesting operation, at which time the blood sample was obtained. (17) (see Methods). Shown on the right side are the results of the double-label Western blot assay ofthe apoB100 and apoB48 in the VLDL fraction. The VLDL fractions were prepared by ultracentrifugation from the plasma of four postoperative normolipidemic liver transplant patients and control subjects. Each plasma sample was obtained after a 14 h fast. * The MBl9 phenotype ofthe apoBl00 and apoB48 bands ofthe postoperative liver transplant recipients' VLDL is shown in parentheses. The MBl9 phenotype of these bands was determined by comparing the 1251/13'I ratios in the apoB48 and apoB 100 bands with those observed in control subjects. (17) (see Methods). Shown on the right side are the results from the double-label Western blot assay of the apoB 100 and apoB48 in the chylomicron fractions. The chylomicrons were prepared by ultracentrifugation from the plasma of postoperative liver transplant patients. The plasma samples were obtained 2 h after a fat-rich meal (see Methods). Liver transplant recipients 1-4 in this table are identical to recipients [1] [2] [3] [4] in Table V . * The MBI9 phenotype of the apoB100 and apoB48 bands of the postoperative liver transplant recipients' chylomicrons are shown in parentheses. The MB19 phenotype of these bands was determined by comparing the 1251/1311 ratios in the apoB48
and apoB 100 bands with those observed in control subjects.
"chylomicron fraction") is made in the liver. However, it is important to add a cautionary statement regarding the sensitivity of the 1251/1311IWestern blot MBl9 phenotyping assay. This assay system is probably not sufficiently sensitive to detect a 5% hepatic contribution to the apoB48 pool or a 5% intestinal contribution to the apoB 100 pool. However, control LDL and postprandial VLDL mixing experiments (data not shown) have indicated that the Western blot assay is capable of detecting a 15% contribution of the liver to the apoB48 pool or a 15% contribution of the intestine to the apoB 100 pool.
To examine directly the possibility ofapoB100 synthesis by the intestine, we used immunocytochemical techniques to examine the duodenal, jejunal, and ileal biopsy specimens as well as liver biopsy specimens from eight organ donors. Monoclonal antibodies that bind to the amino-terminal portion of apoB100 (MB3, MBI 1, and MB24) bound strongly to the liver biopsy specimens as well as to all ofthe intestinal biopsy specimens. Antibodies binding to the carboxy-terminal portion of apoB100 (MB43 and MB44) bound to the apoB in hepatocytes. These latter antibodies detected apoB100 in the vascular submucosa of the intestinal enterocytes; however, even when the carboxy-terminal antibodies were incubated with the biopsy specimens at high concentrations, no specific staining of intestinal enterocytes was observed. Examples ofour immunocytochemical studies are shown in Fig. 8 .
Discussion
Plasma and serum samples were collected from liver transplant donors and recipients because we were convinced that the study of these samples would yield unique insights into apolipoprotein physiology. One of the questions that we wanted to address was the proportion ofserum apoE that was synthesized in the liver versus extrahepatic tissues. Prior studies had demonstrated that apoE was synthesized in a wide variety ofextrahepatic tissues and cells, including kidney, adrenal, skeletal muscle, monocyte-macrophages, and the central and peripheral nervous systems (40) (41) (42) (43) (44) (45) (46) (47) . We believed that we could address the issue ofthe proportion of serum apoE that originates in the liver by examining the postoperative serum of liver transplant patients who had received a liver from a subject with a different apoE phenotype. This idea was not unique to our group; just months after we began to collect samples for our study, Kraft et al. reported a retrospective study ofchanges in apoE, apoA-IV, and Lp(a) phenotypes in 18 liver transplant patients (48) . Al tive serum apoE phenotype of the recipient not only changes, but invariably converts to that of the donor (Table I ). The change in serum apoE phenotype, as judged by IEF gels, was almost always complete; we occasionally found evidence for an isoform synthesized by extrahepatic tissues of the recipient (Fig. 2) . We agree with the conclusion ofKraft et al. (48) that at least 90% of the serum apoE is synthesized by the liver. By investigating apoE mRNA levels in a variety oftissues of nonhuman primates, Newman et al. (46) concluded that from 20 to 40% of apoE may be synthesized extrahepatically in these species. It remains conceivable that 20-40% ofapoE is synthesized in extrahepatic tissues in humans but, because of local catabolism ofthe protein, this relatively high degree ofextrahepatic synthesis is not reflected in the serum apoE pool. Roheim and co-workers pointed out in 1979 that relatively high levels of apoE are present in normal human CSF (38) . They recognized two possible ways that apolipoproteins could enter the CSF: through local production and then diffusion into the CSF or through crossing the blood-brain barrier from the plasma, as is the case for certain other serum proteins. Subsequent studies demonstrated that brain tissue (43, 44) , and specifically the astrocytic glia ofthe brain (7), synthesizes apoE. Pitas et al. (8) recently characterized the apolipoproteins and lipoproteins of human and canine CSF, and, like the earlier studies of Roheim et al. (38) , they found that apoE was present in a relatively high concentration in CSF. They also found that CSF apoE was more heavily sialylated than plasma apoE (8) . These facts suggested that at least a portion ofthe apoE in CSF is produced locally. Our study on the CSF of liver transplant patients addressed the issue ofthe origin ofCSF apoE in a novel way: by examining the CSF of four liver transplant patients in whom we had observed a virtually complete change in serum apoE phenotype. We found that the CSF apoE phenotype did not change to the phenotype of the donor liver, implying that the majority of CSF apoE must be synthesized locally (Table II).
Weisgraber and Mahley reported in 1978 that human apoE can form disulfide-linked heterodimers with apoA-II (26) . They demonstrated that these heterodimers are present in the plasma lipoproteins and are not an artifact produced during the preparation of plasma lipoproteins. Apolipoprotein E4 cannot participate in apoE-A-II formation because it lacks a cysteine residue (25) . Recently, Weisgraber and Shinto have demonstrated that apoE3 and apoE2, but not apoE4, can form disulfide-linked homodimers (27, 48a) . In this study, we were able to demonstrate that both hepatic apoE and extrahepatic apoE can participate in the formation of these disulfide-linked complexes (Figs. 5 and 6 ). In their original description ofapoE-A-II heterodimers, Mahley and Weisgraber pointed out that uncertainty remained about whether this disulfide-linked complex was formed in the plasma or was formed intracellularly and secreted directly from cells (26) . Our experiments demonstrating the participation of extrahepatic apoE in apoE-A-II formation support the former possibility. Although both apoE and apoA-II are synthesized in extrahepatic tissues, they are synthesized in different extrahepatic tissues. The extrahepatic synthesis of apoA-II occurs primarily in intestinal enterocytes (49) , a tissue that makes little or no apoE (6, 44, 50) .
Apolipoprotein E is known to be posttranslationally glycosylated at threonine 194 (51) . In human serum, only 20% of the apoE is glycosylated (5 1) . There is some evidence that the apoE produced by some extrahepatic tissue culture cells, such as astrocytes and monocyte-macrophages, is more extensively glycosylated than the apoE in serum (47, 52) . However, it has remained unclear whether the apoE in serum that originates in extrahepatic tissues has a distinct glycosylation pattern, compared with the bulk ofthe serum apoE, which originates in the liver. Data presented in this study suggest that the apoE in serum that originates in extrahepatic tissues may indeed have a distinct glycosylation pattern. We examined a liver transplant recipient (preoperative phenotype 4/3) who received a liver from a donor with the 4/4 phenotype. Postoperatively, the serum apoE phenotype had a typical 4/4 pattern, as judged by IEF. Nevertheless, there were very small amounts ofapoE-A-II heterodimers and apoE homodimers in his plasma; because apoE4 cannot participate in dimer formation (25, 27) , these dimers must have contained apoE3 produced by extrahepatic tissues. Both disulfide-linked complexes in the postoperative serum were of a slightly higher apparent molecular weight, compared with the dimers found in the preoperative serum. However, the size difference disappeared after neuraminidase treatment of the postoperative serum. These findings strongly imply that extrahepatic apoE is more heavily glycosylated than hepatic apoE, and that the different glycosylation pattern persists in the circulation. Ifthe carbohydrate ofextrahepatic apoE were processed in the circulation (either enzymatically or nonenzymatically) so that the glycosylation pattern conformed to the glycosylation pattern observed for the bulk of serum apoE, one would not expect to observe the higher apparent molecular weight of the disulfide-linked complexes containing extrahepatic apoE.
We also studied changes in the phenotype ofapoB100 after liver transplantation, both by immunoassays using the allotype-specific monoclonal antibody MBl9 and immunoassays using Ag-specific antisera. Using the MB 19 immunoassays, we demonstrated in 28 liver transplant patients that the apoB100 phenotype invariably changes completely to that of the donor (Table III) . This finding, which was confirmed by Ag phenotyping studies (Table IV) , is in keeping with the generally accepted notion that the liver synthesizes the vast majority of apoB100 in human plasma (12, 53) . The Ag-specific antibodies that we used for apoB phenotyping were derived from the serum of multiply transfused thalassemic patients. We tested the hypothesis that some liver transplant recipients might make antibodies to novel Ag antigens synthesized by the donor liver; however, no such antibodies were detectable, perhaps because of the therapeutic immunosuppression regimen prescribed for liver transplant recipients.
Apolipoprotein B48 is synthesized in the intestine as a result of the editing of a single nucleotide of the apoB mRNA, which creates a premature stop codon (54, 55) . The editing process in humans is developmentally regulated; in organ cultures, fetal intestine synthesizes primarily apoB100, whereas adult intestine synthesizes primarily apoB48 (56). Kane et al. (10) have demonstrated that apoB48 is virtually the only apoB species in chyle, obtained from thoracic duct drainage, clearly implicating the intestine as a major contributor to the apoB48 observed in triglyceride-rich lipoproteins after a fat-rich meal. Recently, however, Higuchi et al. (11) have reported that a very small percentage of human hepatic apoB cDNA clones have the edited nucleotide, raising the possibility that the human liver might synthesize small amounts of apoB48. If a small percentage of the liver's apoB synthesis were apoB48, it would not be unreasonable to hypothesize that, given the large mass of hepatic tissue, a significant fraction ofthe apo-B48 infasting plasma could be derived from the liver. To address directly the question ofthe tissue origin ofthe apoB48 in fasting plasma, we simultaneously determined the MBl9 phenotype of the apoB48 and apoB 100 in the fasting VLDL of four normolipidemic liver transplant patients using a double-label Western blot assay (28, 32) . Each patient had received a liver from a donor with a different MB19 phenotype. We demonstrated that the MBl9 phenotype of the apoB100 in fasting VLDL changed to the phenotype of the donor. However, it was equally clear that the apoB48 phenotype did not change ( Table  V) , demonstrating that the liver is not a significant source of apoB48 in fasting plasma. It is important to point out that our conclusions are based upon the analysis of a small number of patients, and it remains conceivable that the liver could make a contribution to apoB48 synthesis in some individuals.
Our MB19 phenotyping studies on the postprandial plasma chylomicron fraction of liver transplant patients were quite informative. First, these studies confirmed that the apoB48 present in the buoyant lipoproteins after a meal is synthesized by the intestine; if there were a hepatic contribution to postprandial apoB48 production in humans, it would have to be quite small. Second, and equally interesting, we found that the apoB 100 that is contained within the chylomicron fraction is of hepatic origin. Previously, the fact that the large, triglyceriderich lipoproteins in postprandial plasma contained a significant amount of apoB 100 had suggested to some investigators the possibility that the intestine might synthesize some apoB100. Recently, Cohn and co-workers reported that the apoB100 content of human VLDL rapidly increases after a fat-rich meal; however, these investigators were unable to be certain about the origin ofthis apoB 100 (57) . Our data in liver transplant patients show that the apoB100 in the postprandial plasma "chylomicron fraction" is derived from the liver. Our finding is consistent with the hypothesis that the human liver rapidly secretes large, buoyant, triglyceride-rich apoB100-containing lipoproteins into the plasma in response to the uptake of the remnant lipoproteins of intestinal origin (57, 58) .
Our genetic evidence that the apoB 100 in the plasma chylomicron fraction is of hepatic origin (Table VI) is consistent with the results of our immunocytochemistry studies (Fig. 8) . Using several monoclonal antibodies that bind to apoB100 but not apoB48, we were unable to detect apoB100 in the intestinal enterocytes of organ donors. In contrast to our results, David- (17) have reported immunocytochemical evidence forapoB 100 synthesis in normal intestinal biopsy specimens. The reason for the discrepancy between their findings and ours is not clear. We did not do any metabolic labeling studies on biopsy specimens. In our immunochemical studies, we used different (but nevertheless thoroughly characterized) apoB-specific monoclonal antibodies. One possibility that might explain the discrepant findings is that our immunochemical studies were not sufficiently sensitive to detect small amounts ofapoB100 in the intestinal biopsy specimens. However, it is noteworthy that we were unable to detect apoB100 in the intestinal mucosal cells even when the intestinal biopsy specimens were incubated with very high concentrations of several different apoB100-specific antibodies; with dilute concentrations of these antibodies, we could detect apoB100 in the liver as well as in the submucosal tissues ofthe intestine. Another possibility is that there may be a significant natural variation in the amount of apoB100 production by enterocytes of different individuals; it is possible that the intestinal enterocytes ofour adult organ donors, unlike the normal subjects studied by other investigators (13, 16, 17) , simply did not make apoB100. It is conceivable that the adult human intestine responds to the stress of hospitalization, life support measures, and treatment ofmajor trauma or a cerebrovascular accident (a virtually universal situation with organ donors) by reducing or "shutting off" the very low level synthesis of apoB100 that occurs under normal conditions.
